TRANSLATIONAL SCIENCE EXPERIENCES
This record is part of
a dataset collected by the EU Commission in June-September 2018
. Some of these links will therefore die out with time.
Please see the
overview of courses maintained by ETPLAS
or contact Norecopa for more information.
Owner/Developer: Charles River Laboratories (CRL)
United States of America
01 September 2018
United States of America
|Description:||WHAT IS IN VITRO TOXICOLOGY? HOW IS IT INTEGRATED INTO IN VIVO TOXICOLOGY? WHERE IS ITS FUTURE? Speaker: Clive Roper, Operational Area Manager, In Vitro Sciences – Charles River In vitro testing has been mainstream in toxicology since the 1970’s. A genetox programme starts with in vitro bacterial (Ames), in vitro mammalian prior to testing in the rodent. Skin penetration studies utilizing human skin have virtually replaced in vivo testing for topical products. Other examples are hERG testing for safety pharmacology and in silico QSAR tests in support of genetox and acute toxicology testing. This testing is already very much part of an integrated testing approach incorporating in silico, in chemico and in vitro technologies with in vivo animal models. There are few areas where in vitro assays fully replace in vivo; however, advances in iPSC, 3D tissues and tissue and human-on-a-chip continue apace in pursuit of this goal. Now, we recognize that the advantages of in vitro models are that they utilize human tissue, help us to identify mechanisms, drive translation, screen and help dose setting for animal models as part of a truly 3Rs vision in toxicology. The objective of this presentation is to provide the audience with information on different in vitro, in chemico and in silico (computational) tests within general and investigational toxicology, and explain how the tests are used within the regulatory testing environment within an integrated testing strategy. Specific examples will be used from different areas of toxicology. A vision of the direction for in vitro toxicology will be shared with the audience. APPLICATION OF IN VITRO TISSUE MODELS FOR TOXICOLOGY AND EFFICACY TESTING Speaker: Patrick Hayden, Vice President – MatTek Corp In vivo safety assessment of drugs, chemicals and consumer products has generally been a critical regulatory requirement prior to release of new products onto the market. However, in recent years, many in vitro assays have been developed and validated with the aim of replacing or reducing the use of in vivo tests. In vitro models of human skin and ocular epithelium have been developed that closely reproduce the 3D organotypic structure and function of in vivo tissues. These models have been accepted by international regulatory authorities as replacements for in vivo skin corrosion, skin irritation and ocular irritation. Additional organotypic in vitro human epithelial models including airway, vaginal, gingival and intestinal are also in development or validation for regulatory use. The objective of this presentation is to learn how these tissue models are produced and validated as microphysiological platforms to model highly-relevant and predictive human biology. A detailed discussion of how in vitro models are used by the biopharma industry and government regulators to complement or replace animal models today, and what is on the horizon, will be also be covered. ADVANCES & APPLICATIONS IN USING 3D BIOPRINTED TISSUE FOR IN VITRO TOXICITY TESTING AND DISEASE MODELING Speaker: Jeff Irelan, Director of Tissue Application – Organovo Conventional cell-based in vitro models lack the complexity of native tissue and thus have a limited capacity for predicting tissue-level responses. These systems fail to accurately reproduce in vivo phenotypes because of limited longevity and the inability to reproduce complex intercellular events. Advanced in vitro models, such as 3D bioprinted human tissues, have the potential to enhance animal model studies and improve clinical translation. The multicellular architecture, reproducible functionality, and long-term viability of bioprinted tissues allow for the recapitulation of many of the complex phenotypes of chronic toxicity mechanisms or disease states at a histological and molecular level. Data will be presented from studies on 3D bioprinted human liver and kidney tissues demonstrating utility in modeling drug-induced toxicity and complex diseases such as fibrosis.|
Interactive online resources
Optional / Voluntary
Students, Researchers, Regulators and policy-makers, Teachers and educators, Technicians, Scientific officers / Project managers, Professionals (e.g. veterinarians)
Academia, Industry, Governmental bodies, Contract Research Organizations (CROs), Consulting, SMEs
Continuing Professional Development
In vitro methods
Substantial coverage (e.g. multiple modules)
|Course level on animal species:||
40+ US credits
Some European credits
Did you find what you were looking for?Yes, I found it! No, I did not!
Thanks for your feedback! Please note that we cannot respond unless you supply your email address.
What are you looking for?
Please give us your feedback so we can improve the information on the page. Thank you in advance for your help. Please add your email address if you would like a reply.Please contact us by email if you have any questions.